the Efficacy and Safety of CLAE in R/R T-ALL/LBL
To evaluate the efficacy and safety of CLAE regimen (cladribine + cytarabine + etoposide) in the treatment of relapsed/refractory T-ALL/LBL.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
DRUG: Cladribine
ORR, Objective response rateï¼Œsum of complete response rate and partial response rate, From the date of first study drug administration until the end of Cycle 2 (each cycle is 28 days)
PFS, progression-free survival, From the date of first study drug administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.|OS, overall survival, From the date of first study drug administration until the date of death due to any cause, assessed up to 24 months.
This study is a prospective, open, multiple -centered, sing-arm trial. The major aim of this studies to evaluate the efficacy and safety of CLAE regimen (cladribine + cytarabine + etoposide) in the treatment of relapsed/refractory T-ALL/LBL. The study will include 50 subjects to receive CLAE regimen for reinduction chemotherapy.